Inovelon (rufinamide)
- Region
- 🇪🇺 EU
- Active substance
- rufinamide
- Company
- Eisai GmbH
- Status
- Authorised
- Therapeutic area
- Epilepsy
- EU approval
- Tue 16 Jan 2007
- Application
- EMEA/H/C/000660
- ATC
- N03AF03
- Official record
- www.ema.europa.eu
Indication
Inovelon is indicated as adjunctive therapy in the treatment of seizures associated with Lennox Gastaut syndrome in patients 4 years of age and older.
Regulatory milestones
No milestones recorded in the last year.
Follow Inovelon
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.